Market Intelligence, Clinical Progress, and High-Purity Reagents for Mucin-Targeted Oncology Development
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MUC1 drug discovery, addressing all major modalities.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (ECD) | MUC1 ECD-Fc Fusion Protein. High purity (>95%), Endotoxin <1EU/ug. HEK293 expressed (native mucin-type glycosylation). Sequence Verified. | View MUC1 Products |
| Antigen (C-terminal) | MUC1 C-terminal Domain (MUC1-CT) protein. Intracellular domain for ADC payload targeting and signaling studies. Also ideal for decoy-effect bypass screening. | View MUC1 Products |
| Gene Delivery | MUC1 Lentivirus Premade Particles. Full-length ORF for stable cell line construction. Preserves physiological glycosylation patterns and membrane conformation. | View MUC1 Products |
| Benchmark Ab | Anti-MUC1 (Sequence Reference: Gatipotuzumab). Recombinant positive control recognizing tandem repeat domain. | View MUC1 Products |
| Validator | MUC1 siRNA Set (3 independent sequences). For knockdown verification and specificity controls (KD efficiency >80%). | View MUC1 Products |
| Counter-Screen A | MUC4 Protein. Critical homology check to assess Mucin family cross-reactivity toxicity. | View MUC4 Products |
| Counter-Screen B | MUC16/CA125 Protein. Off-target liability screening (ovarian/breast tissue expression). | View MUC16 Products |
| Related Target A | HER2 (ERBB2). Synergistic dual-targeting strategy for breast and gastric cancers; MUC1-CT interacts with HER2 intracellular domain. | View HER2 Products |
| Related Target B | CD3. Essential for bispecific T-cell engager (BiTE) design. | View CD3 Products |
| Related Target C | TROP2 (TACSTD2). Parallel ADC target with overlapping solid tumor indications (breast, NSCLC). | View TROP2 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval (Glycosylation mismatch) | Human/Mouse/Cyno MUC1 ortholog proteins available with >95% purity; HEK293 expressed to preserve species-specific glycosylation patterns. |
| Mucin subfamily counter-screening (MUC4/MUC16) | Homolog panel proteins (MUC1/MUC4/MUC16) strictly verified by mass spec for selectivity testing. |
| Epitope accessibility under glycan shield / Glycopeptide vs peptide backbone | Native glycosylation state (HEK293) vs aglycosylated (enzyme-treated) protein pairs available, mass spec verified. Allows differentiation of glycoform-specific vs peptide-binding antibodies. |
| Decoy effect (shed MUC1-N / CA15-3) | Specific MUC1-C terminal recombinant proteins to screen for non-shedding binders; high concentration CA15-3 competition assays possible. |
| Internalization efficiency (ADC development) | Full-length Lentivirus particles for live cell imaging and pH-sensitive dye uptake assays (pHrodo). Provides quantitative internalization rate measurement. |
| Lack of Controls | Clinical Benchmark Antibodies (Gatipotuzumab biosimilar) and CA15-3 ELISA standards included. |
| False Positives / Off-target binding | Validated siRNA included for rigorous biological specificity checks; target-negative cell line generation via knockdown >80%. |
Live MUC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MUC1-targeted therapeutics is intensifying, with major players shifting focus from traditional unconjugated mAbs and vaccines to next-generation modalities. First-generation therapies (Gatipotuzumab, Pemtumomab) established safety profiles but faced limited efficacy, largely due to the decoy effect caused by shedding of the N-terminal extracellular domain (CA15-3) into the bloodstream. Consequently, the next wave of R&D is strictly targeting the membrane-retained MUC1-C terminal (intracellular domain) or tumor-specific aberrantly glycosylated epitopes (e.g., Tn, sTn antigens) to overcome steric hindrance from the heavily glycosylated tandem repeat region. The convergence of CA15-3 biomarker diagnostics with therapeutic development is creating companion diagnostic opportunities in breast, ovarian, and pancreatic cancers. Additionally, resistance mechanisms involving GALNT family upregulation, ADAM17-mediated shedding, and MUC1-β-catenin pathway activation are being addressed through combination strategies with chemotherapy/immune checkpoint inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Glycotargeted & MUC1-CT) | MacroGenics, Daiichi Sankyo, Sutro Biopharma, Mersana Therapeutics | Breast, Pancreatic, NSCLC, Ovarian | Internalization Assay (Need full-length Lentivirus for live cell uptake; MUC1-C protein for non-shedding binders); Glycosylation-specific binding (Need native HEK293 ECD vs aglycosylated pairs) |
| CAR-T | Poseida Therapeutics, Cartesian Therapeutics, BioNTech, academic consortiums | Solid tumors (breast, ovarian, multiple myeloma) | Cell surface stability testing (Need Lentivirus-transduced stable lines for long-term culture); Membrane conformation validation (FACS on full-length MUC1 cells) |
| Bispecific | Merck, AstraZeneca, Regeneron, Johnson & Johnson | Refractory breast, ovarian, pancreatic cancer | Heterodimer validation (Need cross-reactive Abs against MUC1 x CD3; HEK293-expressed antigens for native glycosylation) |
| Intracellular Targeting (MUC1-CT) | OncoTherapy Science, OncoRev | Metastatic lesions, refractory solid tumors, leukemia | Subcellular localization assays (Need isolated C-terminal domain protein); Dimerization/DNA-binding assays (MUC1-CT cytoplasmic domain) |
| Vaccine | Immatics, CureVac | Refractory solid tumors | Epitope screening (Need endotoxin <1EU/ug differentially glycosylated peptides/proteins) |
| Small Molecule (MUC1-C) | OncoRev, academic labs | Refractory solid tumors, leukemia | Dimerization/DNA-binding assay (Need MUC1-C cytoplasmic domain protein for biochemical assays) |